TRIAL DETAIL
Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma |
|||
NCT#: |
||||
Conditions: |
Solid Tumors |
|||
Status: |
Ongoing, but not recruiting |
|||
Phase: |
1 |
Start Date 07/01/2006 |
Age of Trial (yrs) 17.8 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
HDAC inhibitor |
|||
Strategy: |
Unblock cell death genes |
|||
Trial Type: |
GIST not specified. GIST patient enrollment unknown. |
|||
Other Protocol IDs: |
PXD101-CLN-9 |
|||
Sponsor: |
Topo/Target A/S |
|||
Patient Contact: |
Nis Nissen, MD
nni@topotarget.com |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Oral |
|||
Trial Notes: |
||||
Trial Links |
Trial Results |
Drug Information |
| Topotarget's webpage about belinostat |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
333 Cedar St |
New Haven |
CT |
06510 |
USA |
|
New York |
NY |
10032 |
USA |
||
1505 Holcombe Blvd. |
Houston |
TX |
77030 |
USA |
|
Copenhagen |
Denmark |
||||
197 Fulham Rd. |
London |
SW3 6JJ |
UK |
||
550 First Avenue |
New York |
NY |
10016 |
USA |